Differentiated thyroid cancer: comparison of therapeutic iodine 131 biological elimination after discontinuation of levothyroxine versus administration of recombinant human thyrotropin
| Autor: | Antonis Perris, Ioannis Ilias, Virginia Tsapaki, Sofia Kottou, Ioulia Christakopoulou, M. Molfetas, Loukia Oros, Dimitris Papadimitriou |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Metabolic Clearance Rate medicine.medical_treatment Levothyroxine chemistry.chemical_element Thyrotropin Antineoplastic Agents Iodine Gastroenterology Whole-Body Counting law.invention Iodine Radioisotopes law Internal medicine medicine Humans Radiology Nuclear Medicine and imaging Thyroid Neoplasms Thyroid cancer Aged business.industry Thyroid Thyroidectomy General Medicine Middle Aged medicine.disease Prognosis Recombinant Proteins Discontinuation Drug Combinations Thyroxine medicine.anatomical_structure Endocrinology Treatment Outcome chemistry Chemotherapy Adjuvant Recombinant DNA Body Burden Female Radiopharmaceuticals Effective half-life business Relative Biological Effectiveness medicine.drug Half-Life |
| Zdroj: | Annals of nuclear medicine. 20(1) |
| ISSN: | 0914-7187 |
| Popis: | The biological elimination of therapeutic 131I in patients with differentiated thyroid cancer (DTC), post total or near-total thyroidectomy, was compared after withholding levothyroxine suppression against administration of recombinant human thyrotropin without stopping levothyroxine. In 163 patients (group G1) levothyroxine was withheld before 131I therapy: in 138 patients the tumor was limited to the thyroid bed (group G1.1) and in 25 patients metastases were present (group G1.2). A second group of patients (G2; n = 28) received 131I therapy after administration of recombinant human thyrotropin without stopping levothyroxine. Mean retained 131I activity (as a percentage of the administered dose) was 5%-29% (group G1.1), 20%-43% (group G1.2) and 1%-17% (group G2). The effective half-life of 131I was 0.59-0.69 days (group G1.1), 0.87-1.22 days (group G1.2) and 0.38-0.44 days (group G2). In conclusion, the use of recombinant human thyrotropin to prepare patients with thyroid cancer for therapy with 131I shortens its effective half-life and reduces its retained activity compared to preparation with discontinuation of levothyroxine suppression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink